Eagle Pharmaceuticals Inc (EGRX) - Thursday, Jul 25, 2024
Eagle Pharmaceuticals is facing financial difficulties, including delayed filings, management changes, and potential delisting from the NASDAQ
Endo International (ENDP US): Still in Troubled Waters; No Near-Term Growth Driver Is Seen
Weak Q1 performance, top-selling drug facing generic competition, high debt burden, and ongoing opioid litigations remain major overhangs. Shares...
Para IV Winners & Losers - May 2018
This month’s Para IV developments suggest that there is likely to be benefit to Amneal Pharmaceuticals Inc (AMRX US) on Lialda, BioQ pharma for...
No more insights